Does Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide Interact with Drugs Metabolized By Cyp2d6?
CDI records a moderate classification for Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide and Drugs Metabolized By Cyp2d6. The stored summary is: Co-administration may result in increased plasma concentrations of CYP3A substrates, which could increase or prolong their therapeutic effect and adverse events. The mechanism involves darunavir and cobicistat inhibit cyp3a metabolism. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide Class
- Cytochrome P450 3A Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Darunavir and cobicistat inhibit CYP3A metabolism
What To Tell Your Doctor or Pharmacist
If you are taking Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide and your doctor is considering prescribing Drugs Metabolized By Cyp2d6 (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider